Today in Peak History (December 1-10)
Release time:
2020-08-14
peak (12# March 1 - 10 )
1987 12 8 , the third and fourth workers' congress of Jinhua cement plant passed the "peak spirit" resolution of "unity and struggle, realism and innovation, determination to rise to the top and climb the peak forever.
1987 12 10 , "peak" brand 425# ordinary portland cement was rated as a high-quality product in Zhejiang province.
◆ 1990 12 April, with the approval of the competent department, Jianfeng Cement Group issued personal shares ,300 yuan to the public.
◆ 1990 12 , "peak" brand 425# ordinary portland cement was rated as a high-quality product of the national building materials industry bureau.
◆ 1994 12 February, Jianfeng Group Company entered Zhejiang Province 200 "Maximum Operation Scale" and "Best Economic Benefit" series, and was awarded the title of "Double Good Enterprise" with Good Conversion Operation Mechanism and Good Benefit by Zhejiang Provincial People's Government.
1997 12 January 8 , Taizhou Jianfeng Cement Company was completed and put into operation.
◆ 1998 12 1 , the headquarters of the group company moved to peak building, 88 , Wujiang east road.
◆ 2003 12 January 4 , then chairman of the group company du Zihong was awarded the title of "master of operator management" in Zhejiang province.
◆ In 2010 12 , Jiang Xiaomeng, chairman of the group company, was named China's "2010 Most Socially Responsible Entrepreneur".
◆ 2012 12 September 3 , the "peak" trademark of peak pharmaceutical was recognized by Zhejiang Administration for Industry and Commerce as the famous trademark of Zhejiang Province in 2012 , which is the first provincial famous trademark owned by peak pharmaceutical company since its establishment.
◆ 2013 December# October, Jianfeng Pharmaceutical was recognized as a patent demonstration enterprise in Zhejiang Province.
2015 December# November and July, Yu Jianhong, general manager of the group company, won the honor of "national outstanding entrepreneur in building materials industry. ◆
December 12# April, the "Grape Seed Extract International Business Standard" drafted under the auspices of Tianjin Jianfeng Natural Products Company was officially released. ◆ 2016
12 January 1 , Jianfeng Pharmaceutical won the 2016 Best Brand Value Award at the 7th New Medical Observer Forum. ◆ 2016
12 February , Tianjin Jianfeng Natural Products Company became the first batch of "Science and Technology Demonstration Enterprises" in tianjin development zone ". ◆ 2017
December , Jianfeng Pharmaceutical was recognized by the State Intellectual Property Office as the "National Intellectual Property Demonstration Enterprise" of 2017 ". (Xu Xia finishing)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page